Loading...

BioCardia

OTCPK:BCDA
Snowflake Description

Mediocre balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BCDA
OTCPK
$52M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. The last earnings update was 5 days ago. More info.


Add to Portfolio Compare Print
BCDA Share Price and Events
7 Day Returns
7.5%
OTCPK:BCDA
-1.6%
US Biotechs
-0.7%
US Market
1 Year Returns
-28.3%
OTCPK:BCDA
-5.5%
US Biotechs
3%
US Market
BCDA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
BioCardia (BCDA) 7.5% -1.4% -16.7% -28.3% - -
US Biotechs -1.6% -5.5% -6.5% -5.5% 9.7% 12%
US Market -0.7% -2% 2.4% 3% 39.2% 42%
1 Year Return vs Industry and Market
  • BCDA underperformed the Biotechs industry which returned -5.5% over the past year.
  • BCDA underperformed the Market in United States of America which returned 3% over the past year.
Price Volatility
BCDA
Industry
5yr Volatility vs Market
Related Companies

BCDA Value

 Is BioCardia undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for BioCardia. This is due to cash flow or dividend data being unavailable. The share price is $1.1828.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for BioCardia's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are BioCardia's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:BCDA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-0.35
OTCPK:BCDA Share Price ** OTCPK (2019-05-17) in USD $1.18
United States of America Biotechs Industry PE Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 19.48x
United States of America Market PE Ratio Median Figure of 3,088 Publicly-Listed Companies 17.89x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of BioCardia.

OTCPK:BCDA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OTCPK:BCDA Share Price ÷ EPS (both in USD)

= 1.18 ÷ -0.35

-3.34x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BioCardia is loss making, we can't compare its value to the US Biotechs industry average.
  • BioCardia is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does BioCardia's expected growth come at a high price?
Raw Data
OTCPK:BCDA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -3.34x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
United States of America Biotechs Industry PEG Ratio Median Figure of 27 Publicly-Listed Biotechs Companies 1.32x
United States of America Market PEG Ratio Median Figure of 2,117 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for BioCardia, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on BioCardia's assets?
Raw Data
OTCPK:BCDA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $0.02
OTCPK:BCDA Share Price * OTCPK (2019-05-17) in USD $1.18
United States of America Biotechs Industry PB Ratio Median Figure of 416 Publicly-Listed Biotechs Companies 3.21x
United States of America Market PB Ratio Median Figure of 5,195 Publicly-Listed Companies 1.83x
OTCPK:BCDA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OTCPK:BCDA Share Price ÷ Book Value per Share (both in USD)

= 1.18 ÷ 0.02

63.09x

* Primary Listing of BioCardia.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BioCardia is overvalued based on assets compared to the US Biotechs industry average.
X
Value checks
We assess BioCardia's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. BioCardia has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

BCDA Future Performance

 How is BioCardia expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BioCardia has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
22.6%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is BioCardia expected to grow at an attractive rate?
  • Unable to compare BioCardia's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare BioCardia's earnings growth to the United States of America market average as no estimate data is available.
  • Unable to compare BioCardia's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
OTCPK:BCDA Future Growth Rates Data Sources
Data Point Source Value (per year)
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 22.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 17.5%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.9%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:BCDA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:BCDA Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 1 -10 -14
2018-12-31 1 -11 -14
2018-09-30 1 -10 -14
2018-06-30 1 -10 -13
2018-03-31 1 -9 -13
2017-12-31 0 -9 -12
2017-09-30 1 -9 -12
2017-06-30 1 -8 -13
2017-03-31 1 -7 -12
2016-12-31 1 -6 -10
2016-09-30 1 -4 -7
2016-06-30 1 -5 -7

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if BioCardia is high growth as no earnings estimate data is available.
  • Unable to determine if BioCardia is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:BCDA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from BioCardia Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:BCDA Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -0.35
2018-12-31 -0.36
2018-09-30 -0.36
2018-06-30 -0.35
2018-03-31 -0.34
2017-12-31 -0.32
2017-09-30 -0.35
2017-06-30 -0.47
2017-03-31 -0.67
2016-12-31 -1.23
2016-09-30 -4.20
2016-06-30 -4.22

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if BioCardia will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of BCDA’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. BioCardia's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access BioCardia's filings and announcements here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess BioCardia's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
BioCardia has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

BCDA Past Performance

  How has BioCardia performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare BioCardia's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • BioCardia does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare BioCardia's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare BioCardia's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
BioCardia's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from BioCardia Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:BCDA Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 0.64 -14.07 5.68 0.21
2018-12-31 0.63 -13.99 5.76
2018-09-30 0.62 -13.83 6.00
2018-06-30 0.67 -13.29 6.04
2018-03-31 0.54 -13.02 6.30
2017-12-31 0.48 -12.31 6.40
2017-09-30 0.52 -12.40 6.44
2017-06-30 0.50 -12.66 6.04
2017-03-31 0.54 -11.69 5.33
2016-12-31 0.58 -10.31 4.11
2016-09-30 0.65 -6.64 2.91
2016-06-30 0.74 -6.62 2.85
2016-03-31 0.83 -6.44 2.95
2015-12-31 0.90 -6.70 3.73
2015-03-31 0.90 -10.32 4.86
2014-12-31 0.82 -10.21 4.47
2013-12-31 1.51 -5.52 3.37

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if BioCardia has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if BioCardia has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if BioCardia improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess BioCardia's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
BioCardia has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

BCDA Health

 How is BioCardia's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up BioCardia's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • BioCardia is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • BioCardia's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of BioCardia's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 2.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from BioCardia Company Filings, last reported 1 month ago.

OTCPK:BCDA Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 0.82 1.49 2.84
2018-12-31 3.79 0.00 5.36
2018-09-30 2.94 0.00 4.82
2018-06-30 5.76 0.00 6.83
2018-03-31 8.21 0.00 9.65
2017-12-31 11.13 0.00 12.69
2017-09-30 13.79 0.00 15.13
2017-06-30 16.08 0.00 16.91
2017-03-31 18.35 0.00 19.03
2016-12-31 20.58 0.00 21.35
2016-09-30 -10.02 6.91 0.55
2016-06-30 -6.86 6.49 1.69
2016-03-31 -3.44 5.67 3.56
2015-12-31 -3.44 5.67 3.56
2015-03-31 1.19 0.00 1.83
2014-12-31 -4.90 7.50 3.18
2013-12-31 0.85 0.00 1.37
  • BioCardia's level of debt (181.5%) compared to net worth is high (greater than 40%).
  • BioCardia had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • BioCardia has less than a year of cash runway based on current free cash flow.
  • BioCardia has less than a year of cash runway if free cash flow continues to grow at historical rates of 27.4% each year.
X
Financial health checks
We assess BioCardia's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. BioCardia has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

BCDA Dividends

 What is BioCardia's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from BioCardia dividends.
If you bought $2,000 of BioCardia shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate BioCardia's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate BioCardia's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:BCDA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2000 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as BioCardia has not reported any payouts.
  • Unable to verify if BioCardia's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of BioCardia's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as BioCardia has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess BioCardia's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can BioCardia afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. BioCardia has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

BCDA Management

 What is the CEO of BioCardia's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Peter Altman
COMPENSATION $1,980,334
AGE 51
TENURE AS CEO 17.3 years
CEO Bio

Dr. Peter A. Altman, Ph.D. has been Chief Executive Officer and President of BioCardia, Inc. since 1999. Dr. Altman served as an acting Chief Executive Officer of Lumen Therapeutics from 2004 to 2005. He served as Founding Chief Executive Officer of Expression Diagnostics, Inc., from 2000 to 2003. Dr. Altman served as founding President and Chief Executive Officer for XDx, Inc. from 1998 to 2003. He was also an inventor of the technology that is being developed by medical device start up Sinus Rhythm Technologies, Inc. and has raised more than $20 M for California based life sciences companies, from investors including Kleiner Perkins Caufield and Byers and Texas Pacific Group Ventures. Previously, he was with Ventritex (acquired by St Jude Medical) developing AICD technology. He has more than 20 years experience in life science research and product development, is named inventor in 25 US patents and has authored 25 scientific publications. He served as Director of XDx Inc. since 1998. He serves as a Director of BioCardia, Inc. He served as Director of Lumen Therapeutics from 2004 to 2005. Dr. Altman holds PhD in Bioengineering and Pharmaceutical Chemistry in year 2003 from the University of California San Francisco and University of California Berkeley, his Management of Technology certificate from the Haas School of Business, University of California Berkeley and both his Master of Science in year 1990 and Bachelors of Science degrees in Mechanical Engineering in year 1988 from the Columbia University School of Engineering and Applied Sciences.

CEO Compensation
  • Peter's compensation has increased whilst company is loss making.
  • Insufficient data for Peter to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the BioCardia management team in years:

3.3
Average Tenure
52
Average Age
  • The tenure for the BioCardia management team is about average.
Management Team

Peter Altman

TITLE
CEO, President & Director
COMPENSATION
$2M
AGE
51
TENURE
17.3 yrs

Eric Henricus Duckers

TITLE
Chief Medical Officer
COMPENSATION
$610K
AGE
50
TENURE
3.3 yrs

David McClung

TITLE
Vice President of Finance
COMPENSATION
$204K
AGE
55
TENURE
3.2 yrs

Phil Pesta

TITLE
Vice President of Operations
COMPENSATION
$244K
AGE
52
TENURE
7.8 yrs

Ian McNiece

TITLE
Chief Scientific Officer
AGE
64
TENURE
1.5 yrs
Board of Directors Tenure

Average tenure and age of the BioCardia board of directors in years:

3.3
Average Tenure
65
Average Age
  • The tenure for the BioCardia board of directors is about average.
Board of Directors

Simon Stertzer

TITLE
Chairman
COMPENSATION
$14K
AGE
82

Peter Altman

TITLE
CEO, President & Director
COMPENSATION
$2M
AGE
51
TENURE
3.3 yrs

Jay Moyes

TITLE
Independent Director
AGE
64
TENURE
8.3 yrs

Allan Tessler

TITLE
Independent Director
COMPENSATION
$1K
AGE
81
TENURE
7.3 yrs

Tom Quertermous

TITLE
Independent Director
AGE
66
TENURE
17.3 yrs

Fernando Fernandez

TITLE
Independent Director
AGE
57
TENURE
2.6 yrs

Richard Krasno

TITLE
Independent Director
AGE
76
TENURE
2.6 yrs

Rick Pfenniger

TITLE
Independent Director
AGE
63
TENURE
2.6 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by BioCardia insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
02. May 19 Buy Peter Altman Individual 30. Apr 19 01. May 19 11,000 $1.19 $11,912
16. Feb 19 Buy Peter Altman Individual 13. Feb 19 13. Feb 19 50 $1.59 $80
04. Jan 19 Buy Simon Stertzer Individual 24. Dec 18 24. Dec 18 3,333,332 $0.75 $2,499,999
27. Dec 18 Buy Frost Gamma Investments Trust Company 24. Dec 18 24. Dec 18 2,000,000 $0.75 $1,500,000
03. Dec 18 Buy Simon Stertzer Individual 29. Nov 18 29. Nov 18 1,000 $2.10 $2,102
17. Nov 18 Buy Simon Stertzer Individual 14. Nov 18 14. Nov 18 1,000 $2.14 $2,141
17. Nov 18 Buy Peter Altman Individual 14. Nov 18 16. Nov 18 6,400 $2.43 $14,984
13. Nov 18 Buy Simon Stertzer Individual 13. Nov 18 13. Nov 18 1,000 $2.10 $2,100
14. Nov 18 Buy Peter Altman Individual 12. Nov 18 13. Nov 18 3,900 $2.35 $8,412
09. Nov 18 Buy Peter Altman Individual 08. Nov 18 09. Nov 18 500 $2.51 $1,251
07. Nov 18 Buy David McClung Individual 05. Nov 18 05. Nov 18 1,600 $2.56 $4,102
07. Nov 18 Buy Simon Stertzer Individual 02. Nov 18 02. Nov 18 2,000 $2.53 $5,060
07. Nov 18 Buy Peter Altman Individual 02. Nov 18 02. Nov 18 400 $2.52 $1,008
02. Nov 18 Buy Peter Altman Individual 30. Oct 18 30. Oct 18 300 $2.55 $765
29. Oct 18 Buy Peter Altman Individual 25. Oct 18 26. Oct 18 3,850 $2.55 $9,080
16. Oct 18 Buy David McClung Individual 12. Oct 18 12. Oct 18 500 $2.64 $1,318
12. Oct 18 Buy Simon Stertzer Individual 11. Oct 18 11. Oct 18 1,000 $2.70 $2,700
26. Sep 18 Buy David McClung Individual 25. Sep 18 25. Sep 18 2,850 $2.45 $6,988
25. Sep 18 Buy Simon Stertzer Individual 21. Sep 18 21. Sep 18 1,000 $2.43 $2,430
25. Sep 18 Buy Peter Altman Individual 12. Sep 18 20. Sep 18 1,100 $1.82 $1,914
26. Sep 18 Buy Simon Stertzer Individual 18. Sep 18 18. Sep 18 5,000 $1.50 $7,500
20. Sep 18 Buy Peter Altman Individual 18. Sep 18 19. Sep 18 700 $1.71 $1,154
18. Sep 18 Buy Peter Altman Individual 14. Sep 18 18. Sep 18 700 $1.65 $1,110
12. Sep 18 Buy Peter Altman Individual 10. Sep 18 12. Sep 18 1,600 $1.45 $2,184
05. Sep 18 Buy Peter Altman Individual 05. Sep 18 05. Sep 18 5,000 $1.33 $6,650
28. Aug 18 Buy Peter Altman Individual 27. Aug 18 27. Aug 18 1,500 $1.46 $2,190
12. Jun 18 Buy Peter Altman Individual 11. Jun 18 11. Jun 18 3,000 $1.45 $4,350
X
Management checks
We assess BioCardia's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. BioCardia has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

BCDA News

Simply Wall St News

BCDA Company Info

Description

BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia. The company is also developing CardiALLO Cell Therapy System, an investigational culture expanded bone marrow derived from mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system; and Morph vascular access product line, which provides catheter products. BioCardia, Inc. is based in San Carlos, California.

Details
Name: BioCardia, Inc.
BCDA
Exchange: OTCPK
Founded:
$51,607,555
43,631,684
Website: http://www.biocardia.com
Address: BioCardia, Inc.
125 Shoreway Road,
Suite B,
San Carlos,
California, 94070,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OTCPK BCDA New Common Stock Pink Sheets LLC US USD 16. Jul 2015
Number of employees
Current staff
Staff numbers
27
BioCardia employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/20 03:10
End of day share price update: 2019/05/17 00:00
Last earnings filing: 2019/05/15
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.